Nationally Notifiable Infectious Diseases and Conditions, United States: Annual Tables

TABLE 2d. Annual reported cases* of notifiable diseases, by region and reporting area, United States, U.S. Territories, and Non-U.S. Residents, 2021†
Reporting Area Brucellosis Campylobacteriosis Candida auris, clinical § Carbapenemase-producing carbapenem-resistant Enterobacteriaceae Chancroid Chlamydia trachomatis infection
U.S. Residents, excluding U.S. Territories 114 63,409 608 2,328 3 1,613,840
New England 2 3,304 — 22 1 54,208
Connecticut — 715 — — — 14,750
Maine — 271 — — — 3,372
Massachusetts 1 1,441 — — 1 26,950
New Hampshire — 386 — 10 — 3,027
Rhode Island — 278 — 10 — 5,199
Vermont 1 213 — 2 — 910
Middle Atlantic 5 9,115 41 466 — 188,206
New Jersey 2 1,696 — — — 33,425
New York (excluding New York City) — 2,315 — — — 39,719
New York City 3 2,461 — 115 — 61,938
Pennsylvania — 2,643 41 351 — 53,124
East North Central 10 7,797 459 435 1 236,425
Illinois 1 2,078 366 — — 71,836
Indiana — 888 64 182 — 34,755
Michigan 2 1,507 3 204 1 45,473
Ohio 7 1,981 26 — — 56,520
Wisconsin — 1,343 — 49 — 27,841
West North Central 22 6,016 1 98 — 102,673
Iowa 1 1,270 — 28 — 15,620
Kansas — 799 — 12 — 14,851
Minnesota 19 1,559 1 37 — 22,573
Missouri — 1,238 — — — 31,915
Nebraska 2 673 — — — 8,897
North Dakota — 167 — 17 — 3,964
South Dakota — 310 — 4 — 4,853
South Atlantic 10 11,023 52 709 — 329,944
Delaware — 184 2 9 — 4,880
District of Columbia — 5 — — — 6,952
Florida 3 3,873 N N — 104,400
Georgia 2 1,467 1 295 — 67,941
Maryland — 849 30 — U U
North Carolina 3 1,857 1 209 — 63,659
South Carolina 2 625 — — — 36,477
Virginia — 1,718 18 168 — 40,409
West Virginia — 445 — 28 — 5,226
East South Central 3 3,430 — 75 — 111,245
Alabama 1 740 N N — 31,500
Kentucky 1 1,306 — — — 18,392
Mississippi 1 525 — 75 — 22,126
Tennessee — 859 — — — 39,227
West South Central 16 6,278 54 3 — 222,040
Arkansas 2 619 — U — 17,936
Louisiana 1 680 — 3 — 33,759
Oklahoma — 1,039 — — — 20,709
Texas 13 3,940 54 — — 149,636
Mountain 8 5,166 1 268 — 120,680
Arizona 5 1,634 1 246 — 41,498
Colorado 1 1,049 — — — 26,747
Idaho — 491 — — — 6,318
Montana — 273 — — — 4,029
Nevada 1 250 — 5 — 16,348
New Mexico 1 668 — — — 12,441
Utah — 577 — 17 — 11,221
Wyoming — 224 — — — 2,078
Pacific 38 11,280 — 252 1 248,419
Alaska — 91 — — — 5,571
California 30 7,738 N 210 1 191,542
Hawaii 6 490 — 8 — 6,078
Oregon 1 1,094 — 6 — 15,596
Washington 1 1,867 — 28 — 29,632
U.S. Territories 3 105 — 147 — 6,419
American Samoa — — — — — 65
Commonwealth of Northern Mariana Islands — — — — — 207
Guam 3 17 — — — 714
Puerto Rico — 88 — 147 — 4,793
U.S. Virgin Islands — — — — — 640
Non-U.S. Residents — 1 — — — 124
Total 117 63,515 608 2,475 3 1,620,383
  • —: No reported cases — The reporting jurisdiction did not submit any cases to CDC.
  • N: Not reportable — The disease or condition was not reportable by law, statute, or regulation in the reporting jurisdiction.
  • U: Unavailable — The data are unavailable.
  • * Cases are assigned to the reporting jurisdiction submitting the case to NNDSS if the case's country of usual residence is the United States, a U.S. territory, unknown, or country is not reported; otherwise, the case is assigned to the Non-U.S. Residents' category. Country of usual residence is currently not reported by all jurisdictions or for all conditions because this data element is only available in the HL7 generic version 2 and disease-specific message mapping guides. If a jurisdiction sends data in legacy formats, they are not able to send this information. For further information on interpretation of these data, see https://www.cdc.gov/nndss/data-statistics/readers-guides/.
  • † To calculate rates, use the populations provided in Table 8. Note that calculation of rates for the following conditions uses population subgroups as described in note #7 and population counts presented in Table 8: Zika virus infection, congenital; Zika virus disease, congenital; Infant botulism; Congenital rubella syndrome; Perinatal Hepatitis B infection; Perinatal Hepatitis C infection; Haemophilus influenzae, invasive disease; Invasive pneumococcal disease; and Influenza-associated pediatric mortality. Also see Notes #3 and #7.
  • § Candida auris colonization/screening cases are not included in this table. These data are available on the Mycotic Diseases Branch's Tracking Candida auris page (https://www.cdc.gov/fungal/candida-auris/tracking-c-auris.html)
Notes:
  1. These are annual cases of selected infectious national notifiable diseases from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published. Cases are reported by state health departments to CDC weekly. Because source datasets may be updated as additional information is received, statistics in publications based on that source data may differ from what is presented in these tables. Source datasets for the 2021 annual tables were officially closed on March 29, 2023.
  2. The list of national notifiable Infectious diseases and conditions for 2021 and their national surveillance case definitions are available by navigating to the Surveillance Case Definitions | CDC web page, selecting "2021" for the notifiable condition list year, checking "Infectious" conditions, and clicking "Get Notifiable List by Year". CSTE adopted the first coronavirus disease 2019 (COVID-19) national surveillance case definition on April 5, 2020, and they approved a revision to the COVID-19 national surveillance case definition, effective August 5, 2020. On June 17, 2021, a revision to the COVID-19 national surveillance case definition was approved, effective September 1, 2021. Publication criteria for the finalized 2021 data are available at https://wonder.cdc.gov/nndss/documents/2021_NNDSS_Publication_Criteria_03162022.pdf. See also Guide to Interpreting Provisional and Finalized NNDSS Data.
  3. Population estimates for incidence rates are July 1st, 2020, estimates obtained from the National Center for Health Statistics (NCHS) postcensal estimates of the resident population of the United States for April 1, 2010, to July 1, 2020, by year, county, single year of age (range: 0 to 85 years), bridged-race (white, black or African American, American Indian or Alaska Native, Asian, or Pacific Islander), Hispanic ethnicity (not Hispanic or Latino, Hispanic or Latino), and sex (Vintage 2020), prepared under a collaborative arrangement with the U.S. Census Bureau. Population estimates for states released September 22, 2021, are available at https://www.cdc.gov/nchs/nvss/bridged_race/data_documentation.htm. Population estimates for territories are the 2020 mid-year estimates from the U.S. Census Bureau International Data Base, accessed on March 15, 2022, at https://www.census.gov/data-tools/demo/idb/#/country?YR_ANIM=2022. The choice of population denominators for incidence is based on the availability of population data at the time of publication preparation.
  4. Annual tables for 2016 and later years are available on CDC WONDER.
  5. Annual summary reports from 1993–2015 are available as published in the Morbidity and Mortality Weekly Report.
  6. NNDSS annual tables since 1952 are available at CDC Stacks (once in CDC Stacks, select "Annual Reports" in the "Genre" box to the left).
  7. For most conditions, national incidence rates are calculated as the number of reported cases for each infectious disease or condition divided by the U.S. resident population for the specified demographic population or the total U.S. resident population, multiplied by 100,000. When a national notifiable infectious condition is associated with a specific age restriction, the same restriction was applied to the population in the denominator of the incidence rate calculation. In addition, population data from reporting jurisdictions in which the disease or condition was not reportable or not available were excluded from the denominator of the incidence rate calculations.

    Age restrictions in the numerator and denominator are applied for the following childhood conditions:

    • Zika virus disease, congenital (age restriction in numerator and denominator is <1 year)
    • Zika virus infection, congenital (age restriction in numerator and denominator is <1 year)
    • Haemophilus influenzae, invasive disease <5 years (age restriction in numerator and denominator is <5 years)
    • Invasive pneumococcal disease <5 years (age restriction in numerator and denominator is <5 years)
    • Influenza associated pediatric mortality (age restriction in numerator and denominator is <18 years)
    • Infant botulism (age restriction in numerator and denominator is <1 year)
    • Congenital rubella syndrome (age restriction in numerator and denominator is <1 year)
    • Perinatal hepatitis B infection (age restriction in numerator and denominator is ≤24 months)
    • Perinatal hepatitis C infection (age restriction in numerator and denominator is ≤36 months).

    Data for congenital syphilis are aggregated by the infant's year of birth. The rate for congenital syphilis is based upon the number of reported cases per 100,000 live births, using natality data for 2021 (National Center for Health Statistics Natality 2021, as compiled from data provided by the Vital Statistics Cooperative Program). Congenital syphilis cases are usually assigned to the mother's state of residence at the time of delivery. The mother's race and ethnicity are used for race- and ethnicity-specific rates of congenital syphilis cases.

  8. Surveillance data reported by other CDC programs might vary from data reported in these tables because of differences in 1) the date used to aggregate the data, 2) the timing of reports, 3) the source of the data, 4) surveillance case definitions, and 5) policies regarding case jurisdiction (i.e., which jurisdiction should submit the case notification to CDC).
  9. Disease data presented in the 2021 tables reflect impacts of the COVID-19 pandemic, such as changes in exposure-related behavior, healthcare-seeking behavior, disease reporting, and public health investigations.
Suggested Citation: Acknowledgment:
  • CDC acknowledges the local, state, and territorial health departments that collected the data from a range of case ascertainment sources (e.g., healthcare providers, hospitals, laboratories) and reported these data to CDC's National Notifiable Diseases Surveillance System.